Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

LEUVEN, Belgium, November 6 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update for the nine months period ended 30 September 2008.

Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics' clinical development programs continue to progress as anticipated. We are now working hard to prepare for the Phase III clinical program for microplasmin in eye disease following a successful End of Phase II Meeting with the FDA. The recent positive results from our Phase II trials with microplasmin have given us further confidence that this product has the potential to make a real difference in the field of eye disease. We are also developing a good working relationship with our strategic partner Roche as the clinical development of our new anti-cancer antibody TB-403 continues to progress. With our solid financial situation, I believe that ThromboGenics will deliver further important corporate milestones over the next 12 to 18 months as we continue to work to build value for our shareholders."
Financial Update

- In the first nine months of 2008, ThromboGenics achieved

revenues of EUR 30.3 million, mainly from out-licensing activities.

Operating expenses were EUR 17.0 million during this nine month period,

the majority of which were due to R&D expenses related to an increasing

number of clinical development programs.

- As of 30 September 2008, ThromboGenics had EUR 60.9 million

in cash and cash equivalents. This compares to EUR 50.6 million on 30

September 2007 and EUR 40.1 million on 31 December 2007. ThromboGenics

believes that this level of funding will allow it to complete the Phase

III program for the initial indication for microplasmin in eye disease.

- In late July, ThromboG
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... what they believe is the thinnest-possible semiconductor, a ... only three atoms thick. , The University of ... single-layer semiconductor materials can be connected in an ... result could be the basis for next-generation flexible ... and solar technologies. , "Heterojunctions are fundamental elements ...
(Date:8/26/2014)... , Aug. 26, 2014 An analysis by ... of all Mers CoV virus strains has ... back to 2012.  This conservation and sharing of specific ... Synthetic Mers CoV Blocker-Vaccine™ candidate, as it did for the ... both of which have been found to be effective ...
(Date:8/26/2014)... added to the growing case for graphene being ... thing in the high-tech world by the two-dimensional ... of researchers led by a scientist with the ... Laboratory (Berkeley Lab) has reported the first experimental ... materials. The recorded charge transfer time clocked in ...
(Date:8/26/2014)... Ga. , Aug. 26, 2014  ViveBio, ... biological sample collection, stabilization and transportation, announced today ... Laboratory Procurement Services, LLC (LPS) of ... of products in the United States ... new class of ambient temperature dried biological specimen ...
Breaking Biology Technology:Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2Competition for graphene 2ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2
... Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for ... business update. Second Quarter Financial ResultsNet sales ... increase of 50 percent compared with $5.1 million for the ... 59 percent of net sales, compared with gross profit of ...
... BETHESDA, Md., Aug. 11, 2011 The American College ... new ACMG Online Live Learning Center , which ... health care professionals. This valuable, on-demand resource brings the ... live learning offerings such as the Genetics Review Course ...
... GNVC ) today announced that its Board of ... through the adoption of a new Rights Agreement. The new ... 2011, which is the date that GenVec,s existing Rights Agreement ... in connection with the expiration of the existing Rights Agreement ...
Cached Biology Technology:Transgenomic Reports Second Quarter Financial Results 2Transgenomic Reports Second Quarter Financial Results 3Transgenomic Reports Second Quarter Financial Results 4Transgenomic Reports Second Quarter Financial Results 5Transgenomic Reports Second Quarter Financial Results 6Transgenomic Reports Second Quarter Financial Results 7Transgenomic Reports Second Quarter Financial Results 8Transgenomic Reports Second Quarter Financial Results 9ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals 2GenVec Renews Stockholder Rights Plan 2GenVec Renews Stockholder Rights Plan 3
(Date:8/27/2014)... basic research, a growing focus on translating discoveries ... have earned the Herbert Irving Comprehensive Cancer Center ... NewYork-Presbyterian Hospital an $18 million, five-year Cancer Center ... The grant renews the center,s status as one ... New York City and one of only three ...
(Date:8/27/2014)... trans-fats have largely succeeded in sidelining the use ... for its potential contributions to Americans, health conditions. ... the best way to assuage the nation,s insatiable ... Chemical & Engineering News (C&EN), the weekly ... In the article, Stephen Ritter, a senior correspondent ...
(Date:8/27/2014)... thought to be associated with outcomes after the ... of the patient, mechanism of injury, nerve injured, ... operation technique, and repair materials. However, despite numerous ... nerve injuries, there is no agreement regarding the ... dose-effect relationship of the predictors has not been ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... sciences professor Harris Lewin is a recipient of the ... with James R. Cook, of Washington State University. ... recipients in agriculture, chemistry, physics, mathematics, medicine and the ... significant discoveries" in the field of animal agriculture. ...
... from the Walter and Eliza Hall Institute have begun ... a key gene required for the process. The ... blood stem cells, unique ability to self-renew could give ... tissue repair, transplantation and other therapeutic applications. Professor ...
... This release is available in Spanish . ... refrigerators that an estimated 20 percent are lost to spoilage, ... with USDA,s Agricultural Research Service (ARS) are working with colleagues ... The research also may lead to tomatoes that taste better ...
Cached Biology News:Illinois professor awarded 2011 Wolf Prize in Agriculture 2Erg gene key to blood stem cell 'self-renewal' 2Finding a way to extend tomato shelf-life 2
ANTI S. ENT TOX BC2D...
Porcine Serum US Origin 6 Months or Older...
... PlusOne Silver Staining Kit, Protein, ... Heukeshoven and Dernick (1), the kit ... gel electrophoresis systems.Silver Staining Kit, Protein ... of proteins in polyacrylamide gels in ...
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
Biology Products: